Public Employees Retirement Association of Colorado Acquires Shares of 7,440 FibroGen Inc (FGEN)

Public Employees Retirement Association of Colorado acquired a new stake in FibroGen Inc (NASDAQ:FGEN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,440 shares of the biopharmaceutical company’s stock, valued at approximately $353,000.

Other institutional investors have also made changes to their positions in the company. Bank of Montreal Can lifted its position in shares of FibroGen by 2,097.2% in the fourth quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 3,041 shares in the last quarter. Fortaleza Asset Management Inc. lifted its position in shares of FibroGen by 95.0% in the fourth quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 1,700 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 696 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of FibroGen by 41.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 1,147 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its position in shares of FibroGen by 112.6% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 2,336 shares in the last quarter. Institutional investors and hedge funds own 59.24% of the company’s stock.

Shares of FibroGen Inc (NASDAQ:FGEN) opened at $56.50 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen Inc has a 52 week low of $22.75 and a 52 week high of $63.00.

In other FibroGen news, CEO Thomas B. Neff sold 18,900 shares of the business’s stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $42.71, for a total transaction of $807,219.00. Following the sale, the chief executive officer now directly owns 3,060,887 shares of the company’s stock, valued at $130,730,483.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $42.80, for a total value of $85,600.00. Following the sale, the director now directly owns 22,000 shares in the company, valued at $941,600. The disclosure for this sale can be found here. Insiders have sold 353,017 shares of company stock worth $17,863,586 over the last three months. 13.60% of the stock is currently owned by insiders.

FGEN has been the topic of a number of research analyst reports. Mizuho reiterated a “hold” rating and issued a $61.00 target price on shares of FibroGen in a research report on Thursday, November 9th. ValuEngine downgraded FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Four research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $65.67.

WARNING: “Public Employees Retirement Association of Colorado Acquires Shares of 7,440 FibroGen Inc (FGEN)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/20/public-employees-retirement-association-of-colorado-acquires-shares-of-7440-fibrogen-inc-fgen.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply